Actuate Therapeutics (ACTU) Competitors $6.88 -1.63 (-19.15%) Closing price 04:00 PM EasternExtended Trading$6.76 -0.12 (-1.73%) As of 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ACTU vs. OCS, KALV, NRIX, TBPH, GHRS, VALN, VIR, KURA, SANA, and MNMDShould you be buying Actuate Therapeutics stock or one of its competitors? The main competitors of Actuate Therapeutics include Oculis (OCS), KalVista Pharmaceuticals (KALV), Nurix Therapeutics (NRIX), Theravance Biopharma (TBPH), GH Research (GHRS), Valneva (VALN), Vir Biotechnology (VIR), Kura Oncology (KURA), Sana Biotechnology (SANA), and Mind Medicine (MindMed) (MNMD). These companies are all part of the "pharmaceutical products" industry. Actuate Therapeutics vs. Its Competitors Oculis KalVista Pharmaceuticals Nurix Therapeutics Theravance Biopharma GH Research Valneva Vir Biotechnology Kura Oncology Sana Biotechnology Mind Medicine (MindMed) Actuate Therapeutics (NASDAQ:ACTU) and Oculis (NASDAQ:OCS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk. Do institutionals & insiders hold more shares of ACTU or OCS? 22.3% of Oculis shares are owned by institutional investors. 69.3% of Actuate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media favor ACTU or OCS? In the previous week, Oculis had 3 more articles in the media than Actuate Therapeutics. MarketBeat recorded 6 mentions for Oculis and 3 mentions for Actuate Therapeutics. Oculis' average media sentiment score of 0.70 beat Actuate Therapeutics' score of 0.00 indicating that Oculis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Actuate Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oculis 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend ACTU or OCS? Actuate Therapeutics presently has a consensus target price of $20.33, suggesting a potential upside of 195.54%. Oculis has a consensus target price of $35.75, suggesting a potential upside of 107.49%. Given Actuate Therapeutics' higher possible upside, research analysts clearly believe Actuate Therapeutics is more favorable than Oculis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actuate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Oculis 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ACTU or OCS more profitable? Actuate Therapeutics has a net margin of 0.00% compared to Oculis' net margin of -13,958.12%. Actuate Therapeutics' return on equity of 0.00% beat Oculis' return on equity.Company Net Margins Return on Equity Return on Assets Actuate TherapeuticsN/A N/A -281.83% Oculis -13,958.12%-90.31%-67.85% Which has preferable earnings and valuation, ACTU or OCS? Actuate Therapeutics has higher earnings, but lower revenue than Oculis. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioActuate TherapeuticsN/AN/A-$27.28MN/AN/AOculis$780K964.44-$97.43M-$2.67-6.45 SummaryOculis beats Actuate Therapeutics on 6 of the 11 factors compared between the two stocks. Get Actuate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACTU and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACTU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACTU vs. The Competition Export to ExcelMetricActuate TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$142.73M$3.15B$5.76B$10.03BDividend YieldN/A2.28%5.28%4.52%P/E RatioN/A21.4575.4326.15Price / SalesN/A427.65515.98171.98Price / CashN/A45.5837.2059.76Price / Book688.009.5911.536.20Net Income-$27.28M-$53.33M$3.28B$270.56M7 Day Performance-20.09%0.61%0.42%2.70%1 Month Performance-14.21%11.09%10.81%8.77%1 Year Performance-16.10%12.67%61.62%27.50% Actuate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACTUActuate Therapeutics2.0231 of 5 stars$6.88-19.2%$20.33+195.5%+2.9%$142.73MN/A0.0010News CoverageGap DownHigh Trading VolumeOCSOculis2.5418 of 5 stars$16.45+2.0%$35.75+117.3%+43.8%$718.21M$780K-6.162KALVKalVista Pharmaceuticals3.9845 of 5 stars$14.10+4.8%$26.29+86.4%+31.5%$710.05MN/A-3.82100Insider TradeNRIXNurix Therapeutics2.0798 of 5 stars$9.25-1.0%$28.87+212.1%-60.8%$707.55M$54.55M-3.55300Positive NewsTBPHTheravance Biopharma3.747 of 5 stars$13.98+0.7%$21.33+52.6%+72.0%$705.29M$64.38M58.35110Positive NewsGHRSGH Research2.0291 of 5 stars$13.52+0.1%$32.00+136.7%+57.9%$702.38MN/A-18.2410Positive NewsVALNValneva2.1935 of 5 stars$8.23-7.1%$15.33+86.4%+29.0%$699.90M$196.33M-8.39700Analyst ForecastGap DownVIRVir Biotechnology3.3184 of 5 stars$5.00+1.1%$28.44+469.5%-33.0%$692.52M$74.21M-1.25580KURAKura Oncology4.2765 of 5 stars$7.97+0.8%$24.10+202.6%-59.0%$687.98M$53.88M-3.51130News CoverageInsider TradeGap UpSANASana Biotechnology2.834 of 5 stars$2.90-5.4%$8.00+176.3%-40.0%$687.97MN/A-2.73380Positive NewsMNMDMind Medicine (MindMed)2.2864 of 5 stars$9.00+1.4%$24.71+174.6%+62.6%$683.27MN/A-5.8740Positive News Related Companies and Tools Related Companies OCS Competitors KALV Competitors NRIX Competitors TBPH Competitors GHRS Competitors VALN Competitors VIR Competitors KURA Competitors SANA Competitors MNMD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACTU) was last updated on 9/10/2025 by MarketBeat.com Staff From Our PartnersThis stock just surpassed PalantirThe media hasn't caught up to the story yet, but when they do, this stock could leave Nvidia in the dust. I...InvestorPlace | SponsoredOne tiny company just cracked Google’s $19B problemTucked away outside San Antonio sits a facility most Americans don’t know exists. It’s not mining gold or o...True Market Insiders | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredTrump’s reported death a hoaxHow Trump’s latest policies could trigger a full-scale debt collapse… And the specific investments that cou...Porter & Company | SponsoredWorld War 3? Everything Just Changed — and One Tiny Company Is at the Center of It.Trump immediately activated a $5.3 TRILLION AI missile shield — code-named Golden Dome — to stop drone swarms ...Angel Publishing | SponsoredLitecoin’s Creator Backs the World’s First TreasuryBitcoin's corporate adoption story has been written. Litecoin's is just beginning.The Tomorrow Investor | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actuate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Actuate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
